Exiris signs license agreement with the Italian National Institute of Health (ISS) for the use of the ISS cancer stem cell platform.
Mar
01
Latest News
- Exiris a Maker Faire Roma 2024
- Interview with Paola Gallinari on “Osservatorio medico-scientifico”
- Exiris @ RaiNews24
- Exiris presents a “High Complexity-High Efficiency Human Antibody Phage Display Library” at the Festival of Biologics (FOB) 2019, Basel 15-17 October 2019
- Exiris receives European Union research grant for the ETN MAGICBULLET RELOADED project
- New data presented at the 35th European Peptide Symposium, 35EPS, Dublin 26th-31st August 2018
- New data presented at the Peptides and Conjugates for Tumor Targeting, Therapy and Diagnosis, Riminipeptide2018 Congress
- Exiris is awarded a grant from Regione Lazio LIFE 2020
- Exiris files patent application on novel cancer therapeutic antibodies
- New data presented at the 7th Annual World ADC Berlin 2017
© 2016 Exiris Srl · P.IVA 10897561006
Comments are closed.